Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()

BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients. We aimed to overcome crizotinib resistance by combining with the MEK inhibitor trametinib or low-do...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Libo, Wu, Bing, Baruchel, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491461/
https://www.ncbi.nlm.nih.gov/pubmed/28666189
http://dx.doi.org/10.1016/j.tranon.2017.04.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491461/
https://www.ncbi.nlm.nih.gov/pubmed/28666189
http://dx.doi.org/10.1016/j.tranon.2017.04.008

Ejemplares similares